Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

erMune had cash, cash equivalents and available-for-sale securities of approximately $441.9 million.  The March 31, 2013 cash balances include net proceeds from InterMune's concurrent offerings of common stock and convertible notes, which were completed in January 2013.

Guidance for 2013 Revenue and Operating Expenses
The company reiterated its forward-looking financial guidance as announced on January 3, 2013, for Esbriet revenue and operating expenses in 2013:

  • Esbriet revenue: currently projected to be in a range of $40 to $70 million.  This includes:
  • Projected revenue in a range of $40 to $55 million in countries where Esbriet is currently launched (Germany, France, Canada and seven so-called mid-sized European countries).  This range accounts for the impact on revenues of the time required to comply with provincial procedures in Canada before governmental reimbursement of Esbriet in all 10 provinces is typically obtained.
  • Projected revenue in a range of $0 to $15 million in countries where Esbriet is not yet launched at this time.  Countries in this layer of guidance are as follows:
  • Italy – expected launch by mid-June.
  • UK – expected launch by mid-August.
  • Spain – update to be provided in the fourth quarter of 2013.
  • Three mid-sized European countries – Finland launch expected in June; Ireland pricing and reimbursement process conclusion expected in June and if terms are acceptable, a launch in the third quarter; and an update to be provided on the Netherlands in the fourth quarter of 2013.
  • NOTE: The $0 to $15 million range accounts for the impact on revenues of the several quarters needed  to comply with various regional access procedures in Italy (and if pricing and reimbursement terms are agreed in Spain), before patient access to Esbriet can be achieved in every region.
  • R&D expense: currently anticipated to be
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    8. InterMune To Release First Quarter Financial Results On April 24
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, ... launch of their 2nd generation cell therapy POD® design. The 2nd generation portfolio ... also represents a new POD® design. , “G-CON first offered our miniPOD ...
    (Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ( ... increased partnerships with VA and Military Medical centers ... Fiber Density (ENFD) and Sweat Gland Nerve Fiber ... neuropathy ( https://therapath.com/skin ). Demonstration ... Density (ENFD) on punch skin biopsy is a ...
    (Date:7/29/2015)... 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company, is pleased to announce that the final design ... been locked.  Prototypes for industrial and regulatory testing ... application for CE mark clearance to market the ... 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
    (Date:7/29/2015)... ... July 29, 2015 , ... Available ... NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for extreme ... are able to enter fat cells, inhibiting the formation of new fat. Upon ...
    Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
    ... Jr., will address attendees regarding the implementation of Homeland ... www.ndia.org/meetings/9860 on January 27-28, 2009 at the Sheraton National Hotel ... ... 13, 2009 – General Victor E. Renuart, Jr., Commander, ...
    ... Link, Ph.D., of RainDance Technologies, Inc., will present ... a discussion of the commercialization of the use ... in the life sciences, at the LabAutomation2009 conference ... Calif.RainDance Technologies is a provider of innovative microdroplet-based ...
    ... Bionics Inc., "Victhom" (TSX: VHB), announced today the filing ... of sleep apnea and has also disclosed the preliminary ... recently filed a new patent application relating to a ... of sleep apnea/hypopnea using its neuromodulation platform. Late in ...
    Cached Biology Technology:DoD Leader to Address Presidential Biometrics Security Directive at NDIA Conference 2DoD Leader to Address Presidential Biometrics Security Directive at NDIA Conference 3'Biology in Pico-Liter Droplets' is Focus of Presentation at LabAutomation 2009 2'Biology in Pico-Liter Droplets' is Focus of Presentation at LabAutomation 2009 3Victhom announces the completion of the second phase of the apnea therapy development 2Victhom announces the completion of the second phase of the apnea therapy development 3
    (Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
    (Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
    (Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
    Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
    ... mercury is high and increasing in fish in the North ... elsewhere in the Arctic. But a team of scientists ... is wrong in much of the continental Arctic. In ... diverse atmospheric, geological, and biological conditions, "It turns out that ...
    ... RENO - A new collaborative research project funded by ... Obrist at the Desert Research Institute (DRI) will attempt ... of the Earth,s northernmost and most fragile ecosystems. ... environment, but human activities such as fossil fuel combustion, ...
    ... Inc. (OTC.BB:HEPI.OB News), in conjunction with Wayne ... in the College of Liberal Arts and Sciences, ... the Journal of Nutrition & Metabolism , ... hamsters, while inhibiting production of betaine, carnitine, and ...
    Cached Biology News:Virginia Tech research overturns assumption about mercury in the Arctic 2Virginia Tech research overturns assumption about mercury in the Arctic 3New DRI project aimed at understanding Mercury dynamics in the Arctic tundra 2Wayne State cholesterol study shows algal extracts may counter effects of high fat diets 2Wayne State cholesterol study shows algal extracts may counter effects of high fat diets 3
    ... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
    Request Info...
    ...
    LabFax: Immunochemistry...
    Biology Products: